Cybin (HELP) Income from Continuing Operations (2020 - 2022)

Cybin (HELP) posted Income from Continuing Operations of 4552410.37 for Q2 2022, up 186.82% on a QoQ basis from 5243563.44 in Q1 2021.

Cybin (HELP) Income from Continuing Operations (2020 - 2022) Analysis & Trends

Cybin's Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 4552410.37 for Q2 2022.

Quarterly Income from Continuing Operations changed N/A year-over-year to 4552410.37 in Q2 2022, while the trailing twelve-month figure through May 2022 was 162821584.03 (changed N/A YoY) and the FY2026 annual result came in at 147810000.0, down 74.01% from the prior year.
Income from Continuing Operations was 4552410.37 for Q2 2022 at Cybin, up from 5243563.44 in the prior quarter.
Across five years, Income from Continuing Operations topped out at 144237601.97 in Q2 2020 and bottomed at 162128509.13 in Q4 2020.
A 3-year average of 3716796.41 and a median of 1921.84 in 2020 frame the typical range for Income from Continuing Operations.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Income (Continuing) (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-37.09 Mn
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-14.46 Mn
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	227.36 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	1.03 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	727.20 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-26.94 Mn
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	498.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-453.82 Mn
10	Cybin	262.76 Mn	262.76 Mn	-	-

Download Data